Form 4: Director Leslie Norwalk Sells NBIX Shares
Statement of Changes in Beneficial Ownership
Neurocrine Biosciences Director Leslie Norwalk sold 1,250 shares of common stock via a pre-arranged 10b5-1 trading plan.
Summary
- Director Leslie Norwalk sold 1,250 shares of Neurocrine Biosciences (NBIX) common stock.
- The transaction occurred on June 4, 2026, at a weighted average price of $168.0573 per share.
- The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2025.
- Following the transaction, the reporting person retains beneficial ownership of 2,838 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 mechanism, which is a routine administrative action for corporate directors.
Positives
- The sale was conducted under a pre-established Rule 10b5-1 trading plan, indicating the transaction was planned well in advance rather than based on immediate non-public information.
Negatives
- The transaction represents a reduction in the director's direct equity stake in the company.
Risks
- Insider selling can sometimes be perceived negatively by the market, potentially impacting short-term investor sentiment.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard corporate governance practice and typically does not signal a change in the company's fundamental outlook or strategic direction.
Comparison to Industry Standards
- The use of Rule 10b5-1 trading plans is the industry standard for corporate insiders to sell shares while avoiding potential allegations of insider trading.
Stakeholder Impact
- Minimal impact expected as the sale was pre-planned and represents a small portion of the director's holdings.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 2025-09-15 | Date the Rule 10b5-1 trading plan was adopted. |
| 2026-06-04 | Date of the reported stock sale transaction. |
| 2026-06-08 | Date the Form 4 was signed and filed. |
Keywords
NBIX, Neurocrine Biosciences, Insider Trading, Form 4, Director Sale, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.